ADCT at a glance
ADC Therapeutics SA (ADCT, SEC CIK 1771910) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as July 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ADC Therapeutics SA (ADCT) reported revenue of $81.4 million (up 14.9% from FY2024) and a net loss of $142.6 million. Diluted EPS was -$1.12.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding ADC Therapeutics SA (ADCT) shares worth $32.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $81.4M
- +14.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $32.7M · −1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added LOTIS-5 regulatory risk: FDA cited increased Grade 5 adverse events and marginal benefit
- Most material update: Potential withdrawal of ZYNLONTA’s accelerated 3L+ DLBCL approval
- Compliance risk: Confirmatory trial required to verify clinical benefit and maintain current approval
- Operational risk: LOTIS-5 results may impair enrollment in other ZYNLONTA trials
- Commercial risk: Negative benefit-risk perception could reduce ZYNLONTA sales
Management Discussion & Analysis
- Quarterly revenue $21.7M, up 32.2% YoY from $16.4M, driven by ZYNLONTA product revenue of $21.0M, up 33.4%
- Operating margin 66.1% loss vs 188.6% loss YoY, with operating loss $14.4M vs $31.0M
- Best performer: ZYNLONTA product revenue $21.0M vs $15.8M, up 33.4%; license revenue $0.7M in both periods
- Nine-month operating cash use $69.4M vs $110.1M; cash and equivalents $189.2M at September 30
- October financing raised $76.3M; $70.0M term-loan prepayment reduced outstanding principal to $50.0M
- Outlook: fiscal 2026 R&D expense expected to decrease; headwinds include inflation, tariffs and ongoing royalty and debt obligations
AI summary of the ADCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter financial results for the period ended September 30, 2026 announced
- Exhibit 99.1 contains the company’s detailed results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 net product revenue $21.0M, up from $15.8M, supporting commercial traction for ZYNLONTA
- Cash $189.2M at September 30, with expected runway into 2029 after financial restructuring
Item 2.02: Results of Operations and Financial Condition
- Preliminary revenue and cash estimates for three and nine months ended September 30, 2026
- Preliminary cash includes estimated one-time severance and retention payments during Q3 2026
Item 7.01: Regulation FD Disclosure
- New and updated ZYNLONTA trial data scheduled across multiple ASH abstracts, including five oral presentations, December 12–15, 2026
- Investor focus: clinical updates could influence ZYNLONTA’s commercial outlook and ADC Therapeutics’ valuation
Item 8.01: Other Events
- LOTIS-7 ZYNLONTA plus glofitamab: 88.7% ORR and 75.3% CRR in 97 evaluable large B-cell lymphoma patients
- Durability remains encouraging: 79.0% 12-month complete-response rate, with median response duration and PFS not reached
Item EX-99.1: Item EX-99.1
- ASH data broaden ZYNLONTA’s commercial opportunity beyond current late-line DLBCL approval, including MZL and combination therapy with glofitamab
- LOTIS-7: ORR 88.7%, CRR 75.3% among 97 patients, with 12-month complete-response duration rate 79.0%
Item EX-99.2: Item EX-99.2
- ASH update supports ZYNLONTA expansion, with LOTIS-7 ORR 88.7% and CR 75.3% in 97 evaluable patients
- LOTIS-5 met its PFS endpoint, HR 0.73 and p=0.008, but Grade 5 adverse events were higher, 13.2% versus 4.6%
Item EX-99.1: Item EX-99.1
- $86.6M PIPE: 12.9M shares at $1.42 and pre-funded warrants for 48.1M shares at $1.32, creating substantial dilution risk
- Expected net PIPE proceeds $76.3M, extending anticipated cash runway into 2029 and funding ZYNLONTA Phase 3 studies
Item 2.02: Results of Operations and Financial Condition
- Preliminary ZYNLONTA net product revenue released for Q3 2026, providing an early read on commercial performance
- Preliminary cash and cash equivalents as of September 30, 2026, relevant to liquidity and funding runway
Item 1.01: Entry into a Material Definitive Agreement
- $86.6M private placement, including 12.9M shares at $1.42 and 48.1M pre-funded warrants, creating substantial dilution risk
- $70.0M debt prepayment reduces term loans to $50.0M and removes scheduled amortization and minimum liquidity covenant
Item 3.02: Unregistered Sales of Equity Securities
- Private Placement, Lender Warrants and HCR Warrants represent unregistered equity-linked issuances
- Investors should assess dilution, warrant overhang and potential changes to ADC Therapeutics’ capital structure
AI summaries of ADCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ADCT
Don't miss the next ADCT filing
- Alerts as it files. A push when ADCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ADCT, by share count.
- Ask anything. An AI agent that reads every ADCT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Zaki Mohamed | A | Jun 30, 2026 | 213,900 | - |
| GRAHAM PETER J | A | Jun 30, 2026 | 221,100 | - |
| MALLIK AMEET | A | Jun 30, 2026 | 675,000 | - |
| Carmona Jose | A | Jun 30, 2026 | 203,700 | - |
| BIZZARI JEAN-PIERRE | F | Jun 3, 2026 | 12,600 | $3.08 |
| Monges Viviane | F | Jun 3, 2026 | 2,596 | $3.08 |
| Coughlin Timothy | F | Jun 3, 2026 | 12,600 | $3.08 |
| Sandor Victor | F | Jun 3, 2026 | 12,600 | $3.08 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $70.8M | $81.4M |
| Operating Income | - | -$130.7M | -$121.5M |
| Net Income | -$240.1M | -$157.8M | -$142.6M |
| Op. Margin | - | -184.4% | -149.3% |
| Net Margin | - | -222.8% | -175.3% |
| Balance Sheet | |||
| Total Assets | $354.8M | $322.0M | $323.1M |
| Equity | - | -$202.6M | -$185.8M |
| ROE | - | 77.9% | 76.7% |
| Per Share | |||
| EPS | $-2.94 | $-1.62 | $-1.12 |
| Cash Flow | |||
| Operating CF | - | -$123.8M | -$141.2M |
| CapEx | $3.2M | $867K | $264K |
Source: XBRL data in ADC Therapeutics SA (ADCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ADCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $32.7M |
| Q2 2026 | 20 | $26.3M |
| Q1 2026 | 21 | $84.2M |
| Q4 2025 | 19 | $61.9M |
| Q3 2025 | 18 | $65.1M |
| Q2 2025 | 17 | $39.5M |
| Q1 2025 | 16 | $13.8M |
| Q4 2024 | 14 | $6.8M |
- AQR Capital Management+1.59M (+242%)
- Goldman Sachs Group+1.57M (+82%)
- Two Sigma Investments+842.2K (+109%)
- D.E. Shaw & Co+795.2K (+111%)
- Citadel Advisors LLC+393.6K (+19%)
- Morgan Stanley−333.9K (-11%)
- Wells Fargo & Co−268.2K (-87%)
- JPMorgan Chase & Co−94.9K (-62%)
- Citigroup−42.8K (-86%)
- Northern Trust−130 (-0%)
- Renaissance Technologies LLC+384.8K
- Millennium Management−2.90M
- FMR LLC (Fidelity)−132.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 144 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ADCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ADCT SEC filings: frequently asked questions
Which institutions hold ADCT stock?
As of September 30, 2026, the largest ADC Therapeutics SA (ADCT) holders among the 13F filers tracked by SignalX were BlackRock ($8.8 million), Goldman Sachs Group ($4.3 million), Morgan Stanley ($3.3 million), Citadel Advisors LLC ($3.0 million), AQR Capital Management ($2.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ADCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ADC Therapeutics SA (ADCT) reported revenue of $81.4 million (up 14.9% from FY2024) and a net loss of $142.6 million. Diluted EPS was -$1.12. The figures come from the XBRL data in the 10-K.
What did ADCT report in its latest 8-K?
ADC Therapeutics SA (ADCT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter financial results for the period ended September 30, 2026 announced.
What are the latest ADCT SEC filings?
ADC Therapeutics SA (ADCT) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on July 2, 2026.
What is ADCT's SEC CIK number?
ADC Therapeutics SA (ADCT)'s SEC Central Index Key (CIK) is 1771910. EDGAR lists every ADCT filing under that number.
Ask anything about ADCT
The research agent reads ADCT's filings, financials, insider trades and 13F holders, then answers with sources.